Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
In many clinical trials, the primary focus is whether treatment groups differ with respect to the change from baseline to end of therapy in a continuous response variable. Randomized clinical trials often use a repeated measures design in which subjects are followed-up at fixed times throughout the study. With this design, testing for differences between treatment groups with respect to the average change from baseline to end of therapy in the response variable is equivalent to testing for differences between the rates of change in the response variable, assuming the rates of change in each treatment group are linear. This analysis can be performed quite easily using methods such as generalized estimating equations (GEE). However, if the rate of change in the response cannot be assumed linear, the average change from baseline is many times calculated using simply differences between baseline and final measurements and additional data points are not included in the analysis. Instead, we propose using all available data in a repeated measures model that is based on the nonlinear treatment response pattern to estimate the average change from baseline to end of therapy in each treatment group. GEE with robust variance estimation is used for obtaining these model-based estimates of the treatment effect and a simple test for appropriateness of the model is presented. The GEE model presented, in conjunction with the test for appropriateness of the model, form the basis for an adaptive analysis approach for determining the method of estimation of the primary endpoint. This approach results in more efficient estimates of the treatment effect when the response pattern is specified correctly and minimizes the bias in the estimate when the hypothesized response pattern is misspecified. We are motivated by examples in the cystic fibrosis (CF) clinical trial setting and demonstrate the potential for this approach in reducing the sample size required for future CF clinical trials.
Mayer-Hamblett
Nicole
N
Department of Pediatrics, University of Washington, Box 5371, CL-11, Seattle, WA 98195, USA. nicole.hamblett@seattlechildrens.org
Kronmal
Richard A
RA
D003198:Computer Simulation; D003550:Cystic Fibrosis / Q000188:drug therapy; D003627:Data Interpretation, Statistical; D023381:Endpoint Determination / Q000706:statistics & numerical data*; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D015233:Models, Statistical; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D018401:Sample Size